The Potential Role of Omalizumab in the Treatment of Chronic Urticaria
Immunotherapy2014Vol. 6(6), pp. 691–697
Citations Over Time
Abstract
Treatment of chronic urticaria refractory to antihistamines presents a challenge to both people affected with the disease as well as the physicians who treat them. Omalizumab, a monoclonal antibody against IgE, has emerged as one potential solution to this challenge. In several clinical trials published between 2011 and 2013, omalizumab significantly reduced or eliminated symptoms of chronic urticaria. The optimal dose for chronic urticaria is 300 mg administered every 4 weeks, a dose that differs from those used in asthma, which are based on the patient's weight and IgE level. Omalizumab does not appear to cause lasting symptom remission, and the ideal duration of treatment for chronic urticaria has not been defined.
Related Papers
- → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)50 cited
- → EFFECT OF OMALIZUMAB ON PATIENTS WITH CHRONIC URTICARIA: ISSUES WITH THE DETERMINATION OF AUTOIMMUNE URTICARIA(2008)12 cited
- → OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA(2008)9 cited
- → The Potential Role of Omalizumab in the Treatment of Chronic Urticaria(2014)3 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)